Vienna-based health technology company nyra health has raised $23 million in a Series A financing round to accelerate the expansion of its AI-powered neurotherapy platform. The round was led by Armira Growth, with renewed participation from Wellington Partners, Crane Venture Partners, which oversees investments for MassMutual Ventures, and EVER Pharma. The funding will support further product development, expansion across Europe and the United States, and the company’s ambition to define a new global standard for data-driven neurorehabilitation.
Closing Gaps in Neurological Care
Neurological conditions such as stroke, dementia, and traumatic brain injury generate an estimated $76.7 billion in annual costs in Germany alone. Much of this burden stems from reduced therapy intensity after hospital discharge, leading to fragmented follow-up care and avoidable long-term complications. nyra health aims to address this challenge by enabling continuous therapy from inpatient rehabilitation through to structured home-based treatment.
Its MDR Class IIa-certified platform, myReha, is currently used in more than 100 neurological clinics and forms part of the standard aftercare program of the German Pension Insurance. In addition, 28 statutory and private insurers reimburse the therapy automatically, giving more than 40 million insured individuals access to AI-supported home rehabilitation. This level of integration into existing reimbursement structures distinguishes the company within the digital health landscape.
AI-Driven, Adaptive Therapy
myReha uses multimodal artificial intelligence to personalize rehabilitation across speech, cognition, fine motor skills, and daily functioning. Advanced speech models assess pronunciation, word retrieval, syntax, and semantics, while performance metrics such as reaction times and error patterns are continuously analyzed. Based on these inputs, therapy content adapts automatically to each patient’s progress and fatigue levels.
Clinical validation underpins the platform’s positioning, with a randomized controlled trial showing significantly greater improvements in cognitive and language outcomes compared to standard therapy alone. The complementary nyra insights system provides clinicians with real-time progress data, automated documentation, and tools to adjust therapy programs efficiently. An AI-supported Content Studio further enhances personalization by generating tailored therapy materials based on individual performance data.
International Expansion and Technology Development
With the new capital, nyra health plans to deepen its footprint in the DACH region by onboarding additional clinic networks and expanding reimbursement frameworks in Germany, Austria, and Switzerland. The company is also preparing for U.S. market entry in collaboration with an international pharmaceutical partner. At the same time, it is advancing next-generation multimodal AI models for therapeutic interaction and diagnostics through a $4.9 million publicly funded research initiative conducted with leading U.S. universities.
Investors cite the platform’s clinical evidence and integration across the care continuum as key strengths, positioning nyra health as a category-defining player in digital neurorehabilitation. Management emphasizes its mission to make individualized therapy accessible regardless of geography or local healthcare infrastructure. The Series A financing marks a pivotal step in scaling an AI-based approach to neurological recovery on an international level.
As healthcare systems face mounting neurological disease burdens and constrained therapy resources, scalable and reimbursable digital solutions are becoming increasingly critical. nyra health’s latest funding round reflects growing confidence in AI-enabled rehabilitation as both a clinical and economic opportunity. With proven outcomes and expanding international ambitions, the company is positioning itself at the forefront of digital neurotherapy innovation.